User:Kirotsi/sandbox

Darnitsa (Дарниця) is the Ukrainian pharmaceutical company.

Economic performance indicators
Darnitsa ranks second in terms of total sales (2020) in the Ukrainian retail drug market. The company is the leader in the segment of pharmacy-sold packages(2019).

In 2020, according to The Pharma 1000, the company's value reached $360 million, with revenues of $100 million. This is the third result among the Ukrainian pharmaceutical companies.

Foreign economic activity of "Darnitsa" consists of the export of medicines, import of raw materials and equipment. According to 2019 data, the main supplying countries were China (54.35%), India (16.84%), Italy (5.13%), Germany (4.9%). The Darnitsa company exported to 20 countries, most of all to Mongolia (28.22%), Hong Kong (24.65%), Lithuania (21.08%), Bosnia (5.51%), Hungary (4.54%).

The enterprise produces over 250 types of medicines (2019).

At the beginning of 2021, according to Forbes Ukraine and the Work.ua job search portal, the company was among the 50 best employers in Ukraine (position No. 27).

According to "The Vlast of Money" publication ("The power of money"), in 2020, Darnitsa was among the 25 best digital companies in Ukraine. The enterprise has built a hybrid IT infrastructure, uses cloud technologies, and has digitized the drug lifecycle management process.

According to the magazine "Korrespondent", in 2020, the brand Darnitsa was the third in value among all Ukrainian companies. In 2018 and 2019, Darnitsa ranked fourth among the most expensive brands in Ukraine.



History
In 1930, the Kyiv branch of the Ukrainian Institute of Experimental Endocrinology was established, which produced the first drugs in 1932. In particular, hematogen (liquid and tablets). In 1938, new production buildings were put into operation, and by 1940, the production capacity amounted to 4 million units of products, in monetary terms being about 5 million rubles.

During the Second World War, Darnitsa was evacuated to the Urals. In 1950, the Kyiv enterprise was practically restored, and by 1952, the capacity was brought to 15.19 million units of production. In 1954, the branch of the Institute was reorganized into the Darnitsa Chemical and Pharmaceutical Plant. At first, it specialized in the production of solutions for injection in ampoules. In the 1960s, a glass-blowing manufacturing facility with a capacity of 300 million ampoules was put into operation.

In 1976, the Kyiv industrial chemical and pharmaceutical association Darnitsa was established (Darnitsa Chemical & Pharmaceutical Plant, Borshchahivskyi Chemical Pharmaceutical Plant and the Kyiv Vitamin Plant). The products of the combined enterprise were exported to 37 countries of the world. In 1985, the Monastyryshchenskyi Chemical and Pharmaceutical Plant was added to this association.

In July 1991, it became a lease enterprise. In 1993, it was transformed into a collective enterprise Pharmaceutical firm Darnitsa. In 1994, the company became a closed joint stock company (CJSC), and since 2012, it has been a private joint stock company (PrJSC).

In the 1990s, Darnitsa began to re-equip production in accordance with the requirements of the GMP (Good Manufacturing Practice) standard. By 2010, according to a study by O. Posylkina and M. Sidorenko, the company was ahead of other Ukrainian enterprises, having certified 5 sites where 112 different drugs were produced.

During the same period, the main production was modernized. In 1997, the reconstruction of the area for aseptic preparation and bottling of medicines was completed. In 2000, the system for obtaining drinking-quality water was reconstructed, in 2002, a new plant of sterile cephalosporin antibiotics was launched, in 2012, the ampoule production was re-equipped.

In the early 2000s, Darnitsa and four other largest enterprises in Ukraine occupied 21% of the Ukrainian market in monetary terms and 32% in physical terms. Those manufacturers provided more than half of all types of medicines produced by the entire Ukrainian pharmaceutical industry (65 factories, 27 pharmaceutical plants, 119 small enterprises and separate workshops).

In 2006, on the Ukrainian market, Darnitsa was the leader in pharmacy sales in financial terms among the Ukrainian manufacturers, and ranked 4th, taking into account all foreign participants. In 2007, the company was ranked 1st and 5th respectively.

In 2008, with the help of the German company Schäfer, a logistics complex with a total area of 15 thousand square meters was launched, where there is a robotic high-rise warehouse (32 meters) for 10 thousand pallet places.

According to research by Mykola Grebnev and Inna Vinnikova, by 2009 the company had a production area of more than 30 thousand square meters. The production capacity made it possible to produce over 500 million ampoules, 4 billion tablets, 10 million tubes of soft dosage forms, 30 million vials of sterile antibiotics and 35 million drop vials. According to various estimates, the company's share in the Ukrainian pharmaceutical market was about 7%.

In 2010, on the Ukrainian drug market Darnitsa had the following results in terms of sales:
 * 1st position of retail sales in physical terms
 * 5th position of retail sales in monetary terms
 * 3rd position of hospital purchases in physical terms
 * 4th position of hospital purchases in monetary terms

In 2014, the company's net income amounted to 1.2 billion UAH. This was the third place among the Ukrainian pharmaceutical manufacturers. In 2015, Darnitsa also ranked third in terms of sales in pharmacies (among 620 Ukrainian and 1,561 foreign participants).

In 2016, Darnitsa was included into the Top 20 most innovative companies in Ukraine by Forbes Ukraine. The company has implemented an ERP system that allows it to control logistics, plan sales and focus a specific production for a specific demand.

In 2019, the company was rebranded. That year the company became a member of the European Business Association.

Key figures
Head of the Supervisory Board is Volodymyr Zagoriy; Co-owner of the company is Glib Zagoriy; CEO is Andrii Obrizan; executive chairman of  Darnitsa Group is Dmytro Shymkiv.

Social responsibility and charity
According to Natalia Tkachenko, in 2012, Darnitsa was among the top three companies in terms of disclosure of information on corporate social responsibility (among the 20 largest pharmaceutical manufacturers in Ukraine). The researcher came to the conclusion that Darnitsa implements the following areas of social responsibility: Patronage (support of projects in the field of art, science and culture of Ukraine, financing of educational programs and innovative projects in the field of healthcare). Charity (targeted support for vulnerable groups of the population, assistance to injured fellow citizens and defenders during the ATO, innovative projects in the field of healthcare). Sports partnership (jiu-jitsu).

Olga Rogulya gives a number of figures for 2019. Among the philanthropic projects, university scholarships were funded for 3.4 million UAH, a study of public issues and educational activities of The Aspen Institute Kyiv was funded for 1 million UAH, as well as scholarships for participants in the Petro Jacyk International Competition for Experts in the Ukrainian Language.

Assistance to charitable foundations amounted to 23.3 million UAH. Social programs and projects were funded, in particular, "З турботою про співвітчизника" ("Taking care of a compatriot"), #GivingTuesday, "Твій безмежний світ" ("Your boundless world").